Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
121P - DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
Presenter: Nnenna Kanu
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Comprehensive multi-omics profiling identifies prognostic and predictive subtypes in renal cell carcinoma
Presenter: Sanha Park
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Copy number from ulcWGS to predict TNBC molecular subtypes in the IBCSG 22-00 trial
Presenter: Andrea Joaquin Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
124P - Targeting neoantigens in chronic lymphocytic leukemia (CLL) for personalized T cell therapy
Presenter: Gurvinder Kaur
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification
Presenter: Ivan Martinez de Estibariz Royuela
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Genomic and transcriptomic profiles define smokers and non-smokers lung squamous cell carcinoma patients
Presenter: Matteo Canale
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Metastatic migrations in lung cancer: Insights from the PEACE autopsy programme
Presenter: Sonya Hessey
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - NGS prescreening program for refractory solid tumors outside standard indications in a public network of cancer centers
Presenter: Paula Sàbat Viltró
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Transcriptomic analysis of patients with metastatic hormone-sensitive prostate cancer to identify genomic signatures involved in the transition from androgen-dependent to androgen-independent phenotype
Presenter: Giovanna Pecoraro
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Benchmarking whole exome sequencing in the German network for personalized medicine
Presenter: Michael Menzel
Session: Cocktail & Poster Display session
Resources:
Abstract